Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) CFO Paul J. Clancy sold 5,241 shares of Alexion Pharmaceuticals stock in a transaction that occurred on Tuesday, July 10th. The shares were sold at an average price of $131.11, for a total transaction of $687,147.51. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Shares of Alexion Pharmaceuticals traded up $3.17, hitting $134.29, on Thursday, Marketbeat reports. The company had a trading volume of 1,618,271 shares, compared to its average volume of 1,892,821. Alexion Pharmaceuticals, Inc. has a 1-year low of $102.10 and a 1-year high of $149.34. The company has a market cap of $29.35 billion, a P/E ratio of 26.02, a P/E/G ratio of 1.19 and a beta of 1.08. The company has a debt-to-equity ratio of 0.33, a current ratio of 3.35 and a quick ratio of 2.86.
Alexion Pharmaceuticals (NASDAQ:ALXN) last released its quarterly earnings data on Thursday, April 26th. The biopharmaceutical company reported $1.68 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.50 by $0.18. Alexion Pharmaceuticals had a net margin of 14.46% and a return on equity of 13.70%. The firm had revenue of $930.90 million for the quarter, compared to the consensus estimate of $920.50 million. During the same period in the previous year, the company earned $1.38 earnings per share. The company’s quarterly revenue was up 7.0% on a year-over-year basis. equities research analysts expect that Alexion Pharmaceuticals, Inc. will post 6.28 earnings per share for the current year.
Several large investors have recently added to or reduced their stakes in ALXN. Swedbank acquired a new position in shares of Alexion Pharmaceuticals in the second quarter valued at about $101,913,000. Artisan Partners Limited Partnership grew its stake in shares of Alexion Pharmaceuticals by 76.2% in the first quarter. Artisan Partners Limited Partnership now owns 1,048,156 shares of the biopharmaceutical company’s stock valued at $116,827,000 after acquiring an additional 453,196 shares in the last quarter. PointState Capital LP acquired a new position in shares of Alexion Pharmaceuticals in the first quarter valued at about $48,195,000. Redmile Group LLC acquired a new position in shares of Alexion Pharmaceuticals in the first quarter valued at about $45,119,000. Finally, Westfield Capital Management Co. LP acquired a new position in shares of Alexion Pharmaceuticals in the first quarter valued at about $26,648,000. Hedge funds and other institutional investors own 92.22% of the company’s stock.
A number of research analysts have weighed in on the stock. Stifel Nicolaus lifted their price target on shares of Alexion Pharmaceuticals from $151.00 to $155.00 and gave the company a “buy” rating in a research note on Friday, April 27th. BidaskClub raised shares of Alexion Pharmaceuticals from a “hold” rating to a “buy” rating in a research report on Tuesday. Zacks Investment Research raised shares of Alexion Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Tuesday, April 10th. Nomura boosted their price objective on shares of Alexion Pharmaceuticals from $148.00 to $156.00 and gave the stock a “buy” rating in a research report on Thursday, March 15th. Finally, Robert W. Baird set a $160.00 price objective on shares of Alexion Pharmaceuticals and gave the stock a “buy” rating in a research report on Thursday, March 15th. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and nineteen have assigned a buy rating to the company’s stock. The company has a consensus rating of “Buy” and an average target price of $160.00.
Alexion Pharmaceuticals Company Profile
Alexion Pharmaceuticals, Inc, a biopharmaceutical company, develops and commercializes various therapeutic products. The company offers Soliris (eculizumab), a monoclonal antibody for the treatment of paroxysmal nocturnal hemoglobinuria (PNH), a genetic blood disorder; atypical hemolytic uremic syndrome (aHUS), a genetic disease; and generalized myasthenia gravis, a debilitating, complement-mediated neuromuscular disease.
Receive News & Ratings for Alexion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.